Satellos Bioscience (NASDAQ:MSLE) Receives “Buy” Rating from HC Wainwright

Satellos Bioscience (NASDAQ:MSLE)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $11.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 52.80% from the company’s current price.

MSLE has been the topic of several other research reports. Zacks Research upgraded Satellos Bioscience to a “hold” rating in a report on Tuesday, February 10th. Guggenheim initiated coverage on Satellos Bioscience in a report on Tuesday, April 28th. They set a “buy” rating and a $23.00 price target on the stock. Wall Street Zen upgraded Satellos Bioscience from a “strong sell” rating to a “sell” rating in a report on Saturday. Leerink Partners initiated coverage on Satellos Bioscience in a report on Monday, April 6th. They set an “outperform” rating and a $20.00 price target on the stock. Finally, Cantor Fitzgerald initiated coverage on Satellos Bioscience in a report on Wednesday, March 11th. They set an “overweight” rating on the stock. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Satellos Bioscience Trading Up 2.7%

MSLE stock traded up $0.19 during midday trading on Monday, reaching $7.20. The stock had a trading volume of 14,687 shares, compared to its average volume of 61,978. The firm has a fifty day moving average price of $7.52. The stock has a market cap of $149.96 million, a P/E ratio of -4.50 and a beta of 1.60. Satellos Bioscience has a 52-week low of $4.53 and a 52-week high of $13.39.

Satellos Bioscience (NASDAQ:MSLE) last released its earnings results on Friday, May 15th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). On average, analysts predict that Satellos Bioscience will post -2.29 EPS for the current fiscal year.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.